Core Viewpoint - Haisheng Pharmaceutical has signed an innovative drug cooperation agreement with Wanbangde Pharmaceutical to collaborate on the development of treatments for amyotrophic lateral sclerosis (ALS) [1] Group 1: Agreement Details - The agreement was signed on January 12, 2026, and focuses initially on the WP205 product, which has already received orphan drug designation [1] - Haisheng Pharmaceutical will invest 150 million yuan, which will be paid in phases according to the agreement [1] - Upon successful collaboration, Haisheng Pharmaceutical will receive 15% of the global commercialization revenue from the WP205 product [1] Group 2: Future Collaboration - The partnership will later expand to include the development of small molecule cyclic peptide agonists, involving both raw materials and formulations [1] - The agreement is subject to approval by the shareholders' meeting of Wanbangde Pharmaceutical Holdings Group Co., Ltd. [1]

证券代码：002099 证券简称：海翔药业 公告编号：2026-002 浙江海翔药业股份有限公司 关于签订创新药合作协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2、法定代表人：刘同科 特别提示： 1、协议履行过程中，如受到法规政策、市场环境等不可预计或不可抗力因 素的影响，将存在协议无法正常履行的风险。 2、由于药品研发具有高风险、高附加值的特点，药品的前期研发、临床试 验报批到投产的周期长、环节多，容易受到一些不确定性因素的影响。 3、创新药合作协议尚需万邦德医药控股集团股份有限公司股东会审议通过 后生效。 4、公司将根据协议履行情况及后续合作进展，按照证监会、深圳证券交易 所等相关规定及时履行信息披露义务，敬请广大投资者理性投资，注意投资风险。 一、协议签署概况 2026 年 1 月 12 日，浙江海翔药业股份有限公司（以下简称"公司"）与万 邦德医药控股集团股份有限公司全资子公司万邦德制药集团有限公司（以下简称 "万邦德制药"）签订了《创新药合作协议》，双方同意围绕渐冻症适应症，发 挥各自优势，开展相关合作。双方初期合作将聚焦于万邦德制药 ...

Group 1 - The core viewpoint of the news is that Haixiang Pharmaceutical has experienced a significant stock price increase, rising 7.58% on January 9, with a total market value of 11.946 billion yuan and a cumulative increase of 9.94% over four consecutive days [1] - Haixiang Pharmaceutical, established on May 7, 1998, and listed on December 26, 2006, specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and antidiabetic drugs [1] - The company's main business revenue composition includes 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization, 1.02% from other sources, and 0.49% from formulations [1] Group 2 - Among the top circulating shareholders of Haixiang Pharmaceutical, a fund under Southern Fund holds a significant position, having reduced its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which is 0.64% of the circulating shares [2] - The Southern CSI 1000 ETF (512100), established on September 29, 2016, has a current scale of 76.63 billion yuan, with a year-to-date return of 4.96% and a one-year return of 42.74% [2] - The fund manager of Southern CSI 1000 ETF, Cui Lei, has a tenure of 7 years and 65 days, with a total asset scale of 122.76 billion yuan, achieving a best return of 208.53% and a worst return of -15.93% during the tenure [3]

Group 1 - The core viewpoint of the news is that Haixiang Pharmaceutical experienced a stock price increase of 5.07%, reaching 6.84 CNY per share, with a trading volume of 194 million CNY and a turnover rate of 1.84%, resulting in a total market capitalization of 11.072 billion CNY [1] - Haixiang Pharmaceutical, established on May 7, 1998, and listed on December 26, 2006, is located in Taizhou, Zhejiang Province. The company specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and hypoglycemic agents [1] - The revenue composition of Haixiang Pharmaceutical includes 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization services, 1.02% from other sources, and 0.49% from formulations [1] Group 2 - Among the top circulating shareholders of Haixiang Pharmaceutical, a fund under Southern Fund holds a significant position. The Southern CSI 1000 ETF (512100) reduced its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which accounts for 0.64% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a current scale of 76.63 billion CNY. It has achieved a year-to-date return of 3.56%, ranking 2808 out of 5488 in its category, and a one-year return of 42.19%, ranking 1726 out of 4192 [2]

证券代码：002099 证券简称：海翔药业 公告编号：2026-001 浙江海翔药业股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2025 年 4 月 9 日召开 第七届董事会第十三次会议，审议通过了《关于回购股份方案的议案》，同意公 司使用自有/自筹资金以集中竞价交易方式回购部分公司股票（以下简称"本次 回购"），在未来适宜时机用于股权激励或者员工持股计划。本次回购资金总额 不低于人民币 15,000 万元（含），不超过人民币 30,000 万元（含），回购价格 不超过人民币 7.46 元/股（含）。本次回购的实施期限自董事会审议通过本回购 方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 10 日在《证券时报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的《关于回购股份方 案的公告》（公告编号：2025-005）。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关 规定，公司应当在回购期间每个月的前三 ...

Group 1 - The core point of the news is that Haixiang Pharmaceutical experienced a stock price increase of 5.77%, reaching 6.60 CNY per share, with a trading volume of 1.05 billion CNY and a turnover rate of 1.01%, resulting in a total market capitalization of 10.684 billion CNY [1] - Haixiang Pharmaceutical, established on May 7, 1998, and listed on December 26, 2006, is located in Taizhou, Zhejiang Province. The company specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and hypoglycemic agents [1] - The revenue composition of Haixiang Pharmaceutical includes 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization services, 1.02% from other sources, and 0.49% from formulations [1] Group 2 - From the perspective of Haixiang Pharmaceutical's top ten circulating shareholders, Southern Fund's Southern CSI 1000 ETF (512100) reduced its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which accounts for 0.64% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a current scale of 76.63 billion CNY. It has achieved a year-to-date return of 29.23%, ranking 1828 out of 4189 in its category [2]

Group 1 - The company, Haishang Pharmaceutical (002099.SZ), confirmed that it currently does not have any assets related to hydrogen energy or lithium resources [1]

Group 1 - The company, Haixiang Pharmaceutical (002099.SZ), has stated that it is not currently involved in hydrogen energy or lithium resources [1]

Important Matters - WISCO Development plans to acquire equity in WISCO Mining and Luzhong Mining, resulting in stock suspension [1] - Unisplendour intends to purchase equity or full ownership of Ruineng Semiconductor, leading to stock suspension [1] - Heng Rui Medicine's subsidiary received approval for clinical trials of HRS-6257 tablets, with no similar drugs approved in the domestic market [1] - Longpan Technology's subsidiary is reducing production on some lithium iron phosphate production lines for maintenance, a move echoed by several leading manufacturers in the industry [1] Investment Operations - Guoxin Technology has laid out plans for smart driving MCU chips and is developing a high-performance AI chip with 10,000 DMIPS [1] - Juneyao Airlines plans to purchase 25 Airbus A320 series aircraft for $4.1 billion [1] - Spring Airlines intends to buy 30 Airbus A320neo series aircraft, with a transaction amount not exceeding $4.128 billion [1] - Tsinghua Tongfang is making breakthroughs in the open-source HarmonyOS field for product and commercialization [1] - Guangzhou Port is investing 2.353 billion yuan in the intelligent transformation project of the Nansha Port International General Terminal [1] - International Composite Materials plans to invest 1.693 billion yuan to build a project with an annual production capacity of 36 million meters of high-frequency high-speed electronic fiber cloth [1] - State Power Investment Corporation's subsidiary is co-investing with CATL in the Dadu River Danba Hydropower Station project, with a total investment of 15.273 billion yuan [1] - Haisheng Pharmaceutical's invested company has completed the first subject enrollment in the Phase II clinical trial of the innovative drug NWRD06 injection, targeting a specific liver cancer marker [1] Contracts and Collaborations - Chinalco International signed overseas project contracts worth approximately 14 billion yuan [2] - Tianqi Lithium has completed a strategic cooperation with SQM and Codelco [2] - Roman Co., Ltd.'s subsidiary signed a 156 million yuan computing power service project contract [2] - China Duty Free Group's wholly-owned subsidiary signed a duty-free project contract at Beijing Capital International Airport [2] - Reascend Technology's high-silica fiber has begun commercial cooperation with a well-known international aerospace company for long-term product supply [2] - Macro Micro Technology signed a strategic cooperation agreement with a leading domestic transmission company, focusing on GaN power semiconductor devices [2] Capital Operations - Tianqi Co., Ltd. plans to raise no more than 977 million yuan through a private placement for the development of a robot embodiment intelligence system for the automotive industry [2] - SMIC's registered capital in SMIC Southern will increase to $10.077 billion; it plans to acquire 49% equity in SMIC Northern for 40.6 billion yuan [2] - Changan Automobile intends to raise no more than 6 billion yuan through a private placement [2] Share Buybacks - Kweichow Moutai's controlling shareholder, Moutai Group, has cumulatively increased its stake in the company by 3 billion yuan, completing the buyback plan [3] - AVIC Heavy Machinery has been supplying key forgings to several commercial rocket companies [3] - Huihan Co., Ltd. invested 68.25 million yuan to establish a private equity fund, specifically investing in a commercial aerospace company [3] - Sega Technology plans to increase its investment in optical module company Guangcai Xincheng by 275 million yuan to acquire a 20% stake [3]

Group 1: Regulatory Developments - The National Medical Products Administration (NMPA) held a meeting to summarize the regulatory achievements of 2025 and discuss key work for 2026, emphasizing the need for comprehensive regulatory reforms in the cosmetics industry [1] - The meeting highlighted that the Chinese cosmetics market is projected to reach a total transaction value of 1,073.82 billion yuan in 2024, indicating continuous market expansion [1] - Despite the growth, the industry faces structural issues, with over 20,000 registered cosmetics companies but low market concentration and a lack of globally influential brands [1] Group 2: Clinical Innovations and Approvals - The first non-injection epinephrine product, Neffy® (优敏速®), has been approved in China for emergency treatment of severe allergic reactions, marking a significant milestone in drug innovation [4] - HaiXiang Pharmaceutical announced the initiation of Phase II clinical trials for NWRD06, a novel nucleic acid drug aimed at preventing liver cancer recurrence, which is the first of its kind targeting the GPC3 marker [5] - Xinhua Medical received registration for two types of medical devices, enhancing its competitiveness in the in vitro diagnostics market [6] Group 3: Financing and Market Expansion - Beijing Ruifeng Biotechnology completed a C-round financing of over 100 million yuan, aimed at expanding its commercial capabilities and enhancing research and development in both human and animal health [8][9] - Humatrix Medical announced the completion of an A+ round financing of over 100 million yuan, which will be used to advance clinical trials for its core product and expand its product pipeline [10] Group 4: Healthcare Insurance and Spending - The National Healthcare Security Administration reported that from January to November 2025, the total income of the basic medical insurance fund reached 2.632 trillion yuan, with total expenditures of 2.110 trillion yuan, indicating stable fund operations [12]